Tissue Repair
Sydney, Australia· Est.
Australian‑based biotech leveraging beta‑glucan immunomodulation to treat wounds and enhance aesthetic recovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian‑based biotech leveraging beta‑glucan immunomodulation to treat wounds and enhance aesthetic recovery.
DermatologyWound Healing
Technology Platform
Glucoprime® is a proprietary, yeast‑derived beta‑glucan that acts as an immune‑system decoy, stimulating innate pathways to accelerate tissue regeneration and wound repair.
Opportunities
Successful Phase 3 data could unlock large chronic‑wound markets and enable expansion into cosmetic dermatology aftercare, while the unique beta‑glucan mechanism offers potential for additional indications.
Risk Factors
Regulatory approval hinges on Phase 3 outcomes; competition from established wound‑care dressings and the need for substantial manufacturing scale‑up pose financial and execution risks.
Competitive Landscape
Key competitors include 3M, Smith & Nephew, and other polymer‑based dressings; Tissue Repair differentiates through immunomodulatory beta‑glucan technology rather than passive barrier protection.